Calidi Biotherapeutics enters separation agreement with ex-President Boris Minev; $287,500 in payments

Calidi Biotherapeutics, Inc.

Dr. Boris Minev ceased as President, Medical & Scientific Affairs and Section 16 officer effective July 29, 2025.
Separation agreement provides $100,000 negotiated bonus for NNV1 and SNV1 IND approvals and $187,500 severance over 6 months.
Company will pay COBRA premiums for 6 months.
Agreement includes standard release of claims and non-disparagement; effective after 7-day revocation period.

item 1.01item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.